Diffusion Pharmaceuticals, Inc. reported raising $15.8M in a private placement filing on March 16, 2017
Mar 18, 2017
Diffusion Pharmaceuticals, Inc. is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
In The News
-Diffusion Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
Aug 09, 2019 - ENP Newswire
Diffusion Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
Aug 08, 2019 - GlobeNewswire